Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971989 | 0.81 | TAAR1 (0.59) | TAAR1HTR1AHSPA5MPOIDO1 | |
| SCHEMBL11585173 | 0.80 | HTR1A (0.51) | TAAR1HTR1AHSPA5MPOSLC6A4 | |
| SCHEMBL265239 | 0.79 | SLC6A4 (0.61) | TAAR1HTR1AHSPA5MPOIDO1 | |
| SCHEMBL30520716 | 0.79 | SLC6A4 (0.61) | TAAR1HTR1AHSPA5MPOIDO1 | |
| SCHEMBL28626643 | 0.78 | HTR1A (0.49) | TAAR1HTR1AHSPA5MPOIDO1 | |
| SCHEMBL5323248 | 0.77 | S1PR1 (0.49) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL172466 | 0.77 | S1PR1 (0.49) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL51747 | 0.76 | HTR1A (0.64) | TAAR1HTR1AHSPA5MPOIDO1 | |
| SCHEMBL30595395 | 0.76 | HTR1A (0.64) | TAAR1HTR1AHSPA5MPOIDO1 | |
| SCHEMBL678728 | 0.75 | TAAR1 (0.54) | TAAR1HTR1AHSPA5MPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | claimed |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2024-03-07 | — | — | US | claimed |
| WO-2023172497-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING COCAINE USE DISORDER | DREXEL UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2022-07-28 | — | — | US | claimed |
| US-10695302-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2020-06-30 | — | — | US | claimed |
| EP-3062791-B1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | UNIV DREXEL (US) | 2020-01-08 | — | — | EP | claimed |
| CN-109745313-A | The D3 dopamine-receptor stimulant for treating dyskinesia in Parkinson's disease | 德雷克塞尔大学 | 2019-05-14 | — | — | CN | claimed |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2018-04-05 | — | — | US | claimed |
| US-9861594-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2018-01-09 | — | — | US | claimed |
| US-9675565-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2017-06-13 | — | — | US | claimed |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2016-09-08 | — | — | US | claimed |
| EP-3062791-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | Drexel University (US) | 2016-09-07 | — | — | EP | claimed |
| US-9289400-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2016-03-22 | — | — | US | claimed |
| WO-2015066019-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2015-05-07 | — | — | WO | claimed |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | claimed |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | claimed |
| EP-2603215-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | Philadelphia Health and Education Corporation (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | claimed |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | UNIV DREXEL (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2012021629-A2 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695302-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | CHAT, ACHE, SLC18A3 | TAAR1 533/4885HTR1A 102/4885HSPA5 1256/4885 |
| US-20240074993-A1 | METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, COMT, SLC6A2 | TAAR1 590/4885HTR1A 91/4885HSPA5 1210/4885 |
| US-20220233475-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | TAAR1 206/4885HTR1A 83/4885HSPA5 3444/4885 |
| US-20140228380-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | TAAR1 206/4885HTR1A 83/4885HSPA5 3444/4885 |
| US-20180092865-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | TAAR1 355/4885HTR1A 89/4885HSPA5 1633/4885 |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | TAAR1 355/4885HTR1A 89/4885HSPA5 1633/4885 |
| US-20250186369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PRVENTING COCAINE USE DISORDER | CES2, CHAT, SLC18A2 | TAAR1 110/4885HTR1A 78/4885HSPA5 945/4885 |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | TAAR1 206/4885HTR1A 83/4885HSPA5 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.